Rapid Ventricular Response Atrial Fibrillation Clinical Trial
Official title:
Oral Propranolol, Diltiazem, Metoprolol and Verapamil in Atrial Fibrillation Rate Control in Patients With Stable Hemodynamic Status
| Verified date | July 2012 |
| Source | Tehran University of Medical Sciences |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Iran: Ministry of Health |
| Study type | Interventional |
Rate control in atrial fibrillation is a usual battle in emergency departments. Oral
medications have a natural superiority to intravenous ones because they are easy-to-use and
decrease the workload in busy emergency departments.
This study wants to find an effective oral medication for rate control in rapid ventricular
response atrial fibrillation. Propranolol and Metoprolol, Diltiazem and Verapamil are
compared in patients with a stable hemodynamic status.
| Status | Completed |
| Enrollment | 90 |
| Est. completion date | December 2011 |
| Est. primary completion date | December 2011 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Age more than 18 years old - Stability in hemodynamic Exclusion Criteria: - Systolic blood pressure less than 90 mm Hg - Altered mental status attributable to rapid ventricular response atrial fibrillation - Acute pulmonary edema attributable to rapid ventricular response atrial fibrillation - Chest pain attributable to rapid ventricular response atrial fibrillation - Allergy to Propranolol or Metoprolol or Verapamil or Diltiazem - History of asthma |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Iran, Islamic Republic of | Rasoul-e-Akram Hospital | Tehran |
| Lead Sponsor | Collaborator |
|---|---|
| Tehran University of Medical Sciences |
Iran, Islamic Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Rate less than 100 per minute | Ventricular rate less than 100 per minute after 1 hour of per oral medication administration | In 1 hour | No |
| Secondary | Drugs adverse effects | Drugs adverse effects seen in patients in 2 hours after per oral medication administration | 2 hours | Yes |
| Secondary | Unstability in hemodynamic | Hemodynamic instability (systolic blood pressure less than 90 mmHg, loss of consciousness, pulmonary edema, chest pain) | 2 hours | Yes |